```html

Respiratory Distress Syndrome (RDS) in Newborns

Overview

Respiratory distress syndrome (RDS), also called hyaline membrane disease, is a condition in which a newborn’s lungs are unable to provide enough oxygen to the body due to insufficient surfactant—a substance that keeps the tiny air‑spaces (alveoli) open. Without adequate surfactant, the lungs become stiff, collapse partially, and the infant must work harder to breathe.

• Who it affects: Primarily premature infants, especially those born before 34 weeks gestation. Full‑term infants can develop RDS, but it is far less common.
• Prevalence: In the United States, RDS occurs in roughly 10‑15 % of infants born before 32 weeks and in about 1 % of all live births. Worldwide, an estimated 1‑2 % of all newborns develop RDS, with higher rates in low‑resource settings where prenatal care is limited.
• Onset: Symptoms typically appear within minutes to hours after birth.

Symptoms

RDS can range from mild to severe. Typical signs include:

• Rapid, shallow breathing (tachypnea): >60 breaths per minute.
• Grunting: A sound made on exhalation as the baby tries to keep airways open.
• Flaring nostrils and “see‑saw” chest movements.
• Retractions: Pulling in of the chest wall, abdomen, or neck muscles during inhalation.
• Low oxygen saturation: Measured by pulse oximetry (<90 % is concerning).
• Cyanosis: Bluish color of lips or skin indicating low oxygen.
• Apnea episodes: Pauses in breathing that may last a few seconds to minutes.
• Feeding difficulties: Due to fatigue and low oxygen, the baby may be unable to suck effectively.

Causes and Risk Factors

Primary cause

RDS results from a deficiency of pulmonary surfactant, a phospholipid‑rich fluid produced by type II alveolar cells. Surfactant reduces surface tension, preventing alveolar collapse during exhalation.

Key risk factors

• Prematurity: The most important factor. Surfactant production rises sharply after 34 weeks gestation; babies <28 weeks are at the highest risk.
• Maternal diabetes (pre‑gestational or gestational): High insulin levels can delay surfactant synthesis.
• Cesarean delivery without labor: Labor-associated hormonal changes stimulate surfactant release.
• Maternal chorioamnionitis: Infection can disrupt fetal lung development.
• Multiple gestation (twins, triplets): Higher chance of preterm birth.
• Male sex: Boys are slightly more prone to RDS than girls.
• Genetic factors: Rare mutations affecting surfactant production (e.g., SFTPB, SFTPC).

Diagnosis

RDS is a clinical diagnosis supported by imaging and laboratory tests.

Initial clinical assessment

• Observation of respiratory rate, effort, and oxygen saturation.
• Physical exam for retractions, grunting, and cyanosis.

Chest X‑ray

Classic findings include a “ground‑glass” appearance, low lung volumes, and a reticulogranular pattern. These changes become more evident within the first hour of life.

Blood gas analysis

Arterial or capillary samples show low PaO₂ (partial pressure of oxygen) and high PaCO₂ (partial pressure of carbon dioxide), indicating hypoxemia and respiratory acidosis.

Lung ultrasound (increasingly common)

Shows a “white‑out” pattern due to fluid‑filled alveoli and can be performed at the bedside without radiation exposure.

Surfactant level testing (research setting)

Direct measurement of surfactant proteins in tracheal aspirates is not routine but may be used in clinical trials.

Treatment Options

Management aims to keep the infant’s oxygen levels adequate while supporting lung development and preventing further injury.

Supportive respiratory care

• Continuous Positive Airway Pressure (CPAP): First‑line for mild‑moderate RDS. Maintains airway pressure (~5‑6 cm H₂O) to keep alveoli open.
• Mechanical ventilation: Required for severe RDS or when CPAP fails. Modern ventilators use volume‑targeted or high‑frequency oscillatory modes to reduce barotrauma.
• Supplemental oxygen: Titrated to keep SpO₂ between 90‑95 % (per NICHD guidelines).

Exogenous surfactant therapy

Administration of surfactant (e.g., beractant, poractant alfa) directly into the trachea improves lung compliance and oxygenation. Recommended within the first 2 hours of life for infants <32 weeks gestation with RDS.

Pharmacologic adjuncts

• Corticosteroids (antenatal): Prenatal betamethasone or dexamethasone given to mothers at risk of preterm delivery reduces RDS incidence by up to 50 % (WHO, 2022).
• Postnatal steroids: Low‑dose dexamethasone may be used selectively to aid ventilator weaning, but risks of neurodevelopmental impairment limit routine use.
• Inhaled nitric oxide (iNO): Not standard for RDS alone but may be employed if persistent pulmonary hypertension develops.

Fluid and nutrition management

• Restricting fluid intake to avoid pulmonary edema (≈80‑100 mL/kg/day).
• Early parenteral nutrition followed by trophic enteral feeds to promote gut maturation.

Follow‑up therapies

• Gradual weaning from respiratory support as lung compliance improves.
• Developmental care (e.g., kangaroo mother care) to stabilize temperature and reduce stress.

Living with Respiratory Distress Syndrome (Newborns)

While RDS usually resolves as the infant matures, families must navigate the NICU stay and the transition home.

Neonatal Intensive Care Unit (NICU) stay

• Expect a stay of 1‑4 weeks for most preterm infants with RDS, depending on gestational age and complications.
• Daily rounding: ask the care team about oxygen requirements, ventilation settings, and surfactant dosing.
• Maintain a log of vital signs, feeding volumes, and weight gain.

Preparing for discharge

• Parents receive training on home oxygen use, if prescribed.
• Education on recognizing signs of respiratory worsening (see Emergency section).
• Schedule follow‑up appointments with a neonatology or pediatric pulmonology clinic within 1‑2 weeks of discharge.

At home

• Keep the infant’s sleeping environment smoke‑free and maintain a comfortable, stable temperature (68‑72 °F / 20‑22 °C).
• Continue skin‑to‑skin contact (kangaroo care) to improve breathing patterns and bonding.
• Monitor weight daily; inadequate weight gain may indicate feeding or respiratory fatigue.
• Vaccinations: Ensure timely immunizations, especially against RSV (palivizumab prophylaxis for high‑risk infants).

Prevention

Because prematurity is the dominant driver, strategies focus on preventing early birth and promoting lung maturity.

• Antenatal corticosteroids: Administered to mothers at risk of delivery before 34 weeks; reduces RDS, intraventricular hemorrhage, and neonatal mortality (WHO, 2022).
• Optimal maternal health: Good glycemic control for diabetic mothers, smoking cessation, and treatment of infections.
• Progesterone therapy & cervical cerclage: For women with a history of preterm birth to prolong gestation.
• Preventing elective early delivery: Avoiding non‑medically indicated cesarean or induction before 39 weeks gestation.
• Specialist perinatal care: Transfer to a tertiary center with NICU capabilities for high‑risk pregnancies.

Complications

If RDS is severe or prolonged, several serious complications can arise:

• Pulmonary air leak: Pneumothorax or pulmonary interstitial emphysema due to high ventilation pressures.
• Bronchopulmonary dysplasia (BPD): Chronic lung disease defined by need for supplemental O₂ at 36 weeks post‑menstrual age.
• Patent ductus arteriosus (PDA): May worsen respiratory status.
• Intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL): Linked to fluctuating oxygen/CO₂ levels.
• Infections: Prolonged intubation and catheter use increase sepsis risk.
• Neurodevelopmental impairment: Long‑term studies show higher rates of learning and motor difficulties in infants who had severe RDS or BPD.

When to Seek Emergency Care

References

• Mayo Clinic. Hyaline membrane disease (respiratory distress syndrome).
• World Health Organization. Prevention and management of preterm birth. 2022.
• National Institute of Child Health and Human Development (NICHD). Respiratory support for preterm infants.
• Cleveland Clinic. Respiratory distress syndrome in newborns.
• Centers for Disease Control and Prevention (CDC). Preterm birth statistics.
• American Academy of Pediatrics. Guidelines for surfactant therapy and ventilator management.

```